AI Analysis | Feedback

Here are 1-3 brief analogies for TScan Therapeutics (TCRX):

• Like Kite Pharma (now Gilead) or Juno Therapeutics (now Bristol Myers Squibb), but focused on developing TCR-T cell therapies for cancer and infections instead of CAR-T.
• Similar to a company like Moderna or BioNTech, but their proprietary platform discovers and engineers T-cell receptors (TCRs) for treating cancer and chronic infections, rather than developing mRNA-based therapies.

AI Analysis | Feedback

• TCR-T Cell Therapies (e.g., TSC-100, TSC-101, TSC-200, TSC-204): These are a pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies designed to treat various cancers, including hematologic malignancies and solid tumors.
• T-Precision Platform / ImmunoBank: This proprietary technology platform identifies and banks potent, tumor-specific T-cell receptors (TCRs) for use in developing their TCR-T cell therapies.

AI Analysis | Feedback

Major Customers of TScan Therapeutics (TCRX)

TScan Therapeutics (TCRX) is a clinical-stage biopharmaceutical company focused on developing T-cell receptor (TCR) engineered T-cell therapies for the treatment of cancer and other serious diseases. As a company in the drug development phase, it does not sell products directly to individuals (patients). Instead, its primary "customers" are other pharmaceutical or biotechnology companies with whom it forms strategic collaborations for the development, funding, and potential commercialization of its therapeutic candidates.

Their major identified strategic partner and a significant source of funding through collaboration is:

• AstraZeneca (Symbol: AZN)

TScan Therapeutics entered into a significant collaboration and license agreement with AstraZeneca in 2022. This partnership is focused on identifying novel TCR T-cell therapies for five cancer targets. The agreement includes potential upfront payments, research funding, milestone payments, and future royalties, making AstraZeneca a key strategic partner and primary revenue source for TScan Therapeutics at this stage.

AI Analysis | Feedback

• WuXi Advanced Therapies (Parent: WuXi AppTec - Symbol: 2359.HK)
• Cytiva (Parent: Danaher Corporation - Symbol: DHR)

AI Analysis | Feedback

Gavin MacBeath, Ph.D. Chief Executive Officer

Gavin MacBeath serves as the Chief Executive Officer at TScan Therapeutics and is a member of the board of directors. He possesses over two decades of experience in both academia and industry, encompassing company founding and driving research from early discovery to drug approval. Prior to TScan, Dr. MacBeath was the Chief Scientific Officer at Abpro, where he advanced T cell-engaging bispecific antibodies through preclinical development. He also co-founded Merrimack Pharmaceuticals, serving as Senior Vice President of Discovery, and advanced several biologics through IND, Phase 1, and Phase 2 clinical development. He co-founded three oncology companies. His academic career included roles as the first fellow at Harvard's Bauer Center for Genomics Research, an Assistant and Associate Professor at Harvard University, and a Lecturer and Principal Investigator at Harvard Medical School.

Jason Amello Chief Financial Officer and Treasurer

Jason Amello is the Chief Financial Officer and Treasurer at TScan Therapeutics. Before joining TScan, he served as the Chief Financial Officer, Treasurer, and Secretary at Candel Therapeutics, Inc., where he developed financial strategy and supported business development. From 2012 to 2022, he was CFO and Treasurer for Saniona AB, Akebia Therapeutics, Inc., and Ziopharm Oncology Inc. (now Alaunos Therapeutics, Inc.). From 2000 to 2011, Mr. Amello held various finance leadership roles at Genzyme Corporation, including Senior Vice President and Chief Accounting Officer. He advised on Genzyme's mergers and acquisitions and strategic transactions, including its sale to Sanofi for approximately $20 billion. He also served on the Board of Directors for Acer Therapeutics, Inc., which was acquired by Zevra Therapeutics, Inc. Earlier in his career, he spent a decade in business advisory and assurance at Deloitte.

Chrystal Louis, M.D., M.P.H. Chief Medical Officer

Chrystal Louis is the Chief Medical Officer at TScan Therapeutics, bringing two decades of experience in academia and industry. Her expertise spans clinical development, medical affairs, and commercialization, with a track record in regulatory approvals and product launches. Before TScan, Dr. Louis was the Senior Vice President of hematology clinical development at Zentalis Pharmaceuticals. She also held positions of increasing responsibility in medical affairs at CRISPR Therapeutics, Bristol Myers Squibb Company, and Celgene (acquired by BMS), and in clinical development and project leadership at Merrimack Pharmaceuticals. Prior to her industry career, Dr. Louis was an Assistant Professor at Texas Children's Cancer Center and Hematology Service, Baylor College of Medicine, where she contributed to the early development of CAR-T cell therapy products for solid tumor malignancies.

Justin McCue, Ph.D. Chief Technology Officer

Justin McCue is the Chief Technology Officer at TScan Therapeutics.

Zoran Zdraveski, J.D., Ph.D. Chief Legal and Strategy Officer and Secretary

Zoran Zdraveski serves as the Chief Legal and Strategy Officer and Secretary at TScan Therapeutics.

AI Analysis | Feedback

The key risks to TScan Therapeutics (symbol: TCRX) are primarily centered around clinical development challenges, financial viability, and the efficacy of its lead therapeutic candidates.

1. Clinical Trial Delays and Regulatory Hurdles: TScan Therapeutics has experienced significant delays in its clinical timelines, particularly for its lead product candidate, TSC-101, and solid tumor trials. Regulatory feedback has necessitated additional patients for studies, pushing back the expected start of the pivotal TSC-101 study and delaying the forecast for solid tumor program launches. These delays can substantially impact the company's ability to bring products to market and generate revenue, leading to analyst downgrades and reduced price targets.
2. Unprofitability and Cash Burn: TScan Therapeutics is currently operating at a loss and is not projected to achieve profitability within the next three years. The company faces concerns regarding its cash burn rate and its capacity to secure sufficient funding for ongoing and future studies. Although the company has implemented workforce reductions to extend its cash runway, this underscores the persistent financial pressures.
3. Clinical Efficacy and Safety Concerns for Lead Product: Specific clinical risks for TScan's lead candidate, TSC-101, include an 18% relapse rate observed in recent trials and potential Graft-versus-Host Disease (GvHD) risks. Such efficacy and safety concerns directly threaten the success and market adoption of their most advanced therapeutic program.

AI Analysis | Feedback

The accelerating development and potential widespread adoption of allogeneic (off-the-shelf) T-cell therapies. TScan Therapeutics currently focuses on autologous (patient-specific) T-cell receptor (TCR) engineered T-cell therapies. Allogeneic therapies aim to provide readily available, standardized treatments, potentially overcoming the complex manufacturing, logistical challenges, and high costs associated with autologous therapies. If allogeneic approaches demonstrate comparable efficacy and safety in clinical trials, their inherent advantages in accessibility and scalability could significantly disrupt the market for autologous cell therapies, potentially reducing the addressable market or competitive edge for TCRX's pipeline.

AI Analysis | Feedback

TScan Therapeutics (TCRX) is developing T-cell receptor (TCR)-engineered T cell (TCR-T) therapies for various cancers and is also conducting early-stage research in autoimmune diseases. The addressable markets for their main products or services are as follows:

• For TSC-101, a lead candidate targeting acute leukemia, the potential market is estimated to be $100-$200 million in the U.S.
• TScan Therapeutics targets sizable markets for Acute Myeloid Leukemia (AML) and Human Papillomavirus (HPV)-associated cancers, which are estimated at $1.8 billion and $5.9 billion, respectively. The region for these market sizes is not specified in the provided sources.

The global TCR therapy market, which encompasses the type of therapies TScan Therapeutics is developing, was an estimated US$362 million in 2024 and grew to US$410.6 million in 2025. This market is projected to reach approximately US$1264.73 million by 2034, with a compound annual growth rate (CAGR) of 13.44% between 2025 and 2034. North America accounted for approximately 45% of the TCR therapy market revenue share in 2024.

AI Analysis | Feedback

1. Advancement and Potential Commercialization of TSC-101: TScan's lead T cell receptor (TCR)-engineered T cell (TCR-T) therapy candidate, TSC-101, designed to prevent relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation, is a primary revenue driver. The company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the pivotal study design for TSC-101. A pivotal trial for TSC-101 is planned for launch in the second quarter of 2026, with a readout supporting full approval anticipated in the second half of 2027. The FDA's Regenerative Medicine Advanced Therapies (RMAT) designation for TSC-100 and TSC-101 could also accelerate the development and approval pathway.
2. Expansion of the Hematologic Malignancies Pipeline: TScan plans to broaden its hematologic malignancies program by submitting Investigational New Drug (IND) applications for two additional TCR-T product candidates in the fourth quarter of 2025. These new candidates aim to expand the human leukocyte antigen (HLA) coverage, potentially increasing the addressable patient population. Phase 1 development for these new candidates is projected to begin in the second half of 2026, subject to additional funding. This expansion could lead to a more robust pipeline and additional revenue streams in the future.
3. Strategic Collaborations: Existing and future strategic collaborations are a significant source of revenue for TScan. The company has a collaboration agreement with Amgen Inc., which has already contributed to substantial increases in collaboration and license revenue. For example, revenue from collaborations and licenses increased to $2.2 million in Q1 2025 from $566,000 in Q1 2024, primarily due to the Amgen partnership. Additional partnerships leveraging TScan's proprietary platform and ImmunoBank of validated TCRs could generate further milestone payments and potential royalties, contributing to revenue growth.
4. Progression of Solid Tumor Therapies through Preclinical Development and Partnerships: While TScan has paused further enrollment in its PLEXI-T solid tumor trial to prioritize its hematologic malignancies program, the company is continuing with preclinical development of in vivo engineering to treat solid tumors. TScan has also partnered with a third party specializing in the development of a lentiviral-based platform for in vivo engineering of T cells. This strategic shift, although leading to a near-term clinical pause, could lay the groundwork for future revenue streams through new collaborations or the advancement of innovative solid tumor programs within the 2-3 year timeframe. Initial safety and efficacy data from the PLEXI-T trial are still expected in Q1 2026, which could validate the platform for future efforts.

AI Analysis | Feedback

Share Repurchases

• TScan Therapeutics has not made any share repurchases over the last 3-5 years, with share buybacks reported as $0.00.

Share Issuance

• In April 2024, TScan Therapeutics priced an upsized public offering, expecting gross proceeds of approximately $150.1 million from the sale of voting common stock and pre-funded warrants.
• In December 2024, the company announced a $30 million registered direct offering through the sale of pre-funded warrants.
• TScan Therapeutics completed its Initial Public Offering (IPO) in July 2021, aiming to raise $100 million by offering 6.3 million shares.

Inbound Investments

• In December 2024, Lynx1 Capital Management LP and an investment fund advised by Lynx1 invested approximately $30 million in TScan Therapeutics through a registered direct offering of pre-funded warrants at a 37% premium.
• As of December 31, 2024, institutional investors collectively held 52% of the company's shares.
• Major institutional shareholders include Lynx1 Capital Management LP, BVF Inc/il, Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc.

Capital Expenditures

• Over the last 12 months, TScan Therapeutics reported capital expenditures of -$5.07 million.
• The company expects its existing cash and marketable securities, bolstered by recent offerings, to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
• A strategic prioritization announced in November 2025 aims to extend the cash runway, including coverage for capital expenditures, into the second half of 2027, with a focus on advancing its hematologic program.